Holen Sie sich die Stockscreener-App
48.51
0.46%
-0.2045
Schlusskurs vom Vortag:
$48.71
Offen:
$48.4
24-Stunden-Volumen:
1.70M
Relative Volume:
0.33
Marktkapitalisierung:
$97.85B
Einnahmen:
$42.06B
Nettoeinkommen (Verlust:
$7.96B
KGV:
13.83
EPS:
3.5062
Netto-Cashflow:
$5.64B
1W Leistung:
-0.81%
1M Leistung:
+2.35%
6M Leistung:
+25.48%
1J Leistung:
+43.92%
1-Tages-Spanne:
$48.30
$48.69
1-Wochen-Bereich:
$48.30
$49.44
52-Wochen-Spanne:
$31.71
$49.44
Gsk Plc Adr Stock (GSK) Company Profile
Vergleichen Sie GSK mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GSK
Gsk Plc Adr
|
48.51 | 98.27B | 42.06B | 7.96B | 5.64B | 3.5062 |
|
LLY
Lilly Eli Co
|
1,064.15 | 932.42B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
208.27 | 506.75B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
224.58 | 396.44B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
135.22 | 259.09B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
100.15 | 246.17B | 63.90B | 19.05B | 13.05B | 7.5596 |
Gsk Plc Adr Stock (GSK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-25 | Hochstufung | BofA Securities | Underperform → Neutral |
| 2025-06-03 | Herabstufung | Berenberg | Buy → Hold |
| 2025-04-15 | Eingeleitet | Exane BNP Paribas | Neutral |
| 2025-02-12 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-11-15 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-11-12 | Herabstufung | Jefferies | Buy → Hold |
| 2024-10-31 | Herabstufung | Guggenheim | Buy → Neutral |
| 2024-07-08 | Herabstufung | UBS | Buy → Neutral |
| 2024-05-30 | Eingeleitet | Goldman | Neutral |
| 2024-03-04 | Hochstufung | Guggenheim | Neutral → Buy |
| 2024-02-13 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-01-23 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-01-16 | Fortgesetzt | UBS | Buy |
| 2024-01-03 | Hochstufung | Jefferies | Hold → Buy |
| 2023-07-14 | Eingeleitet | HSBC Securities | Reduce |
| 2023-03-17 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2023-02-27 | Fortgesetzt | Goldman | Buy |
| 2023-01-03 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-12-05 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2022-11-11 | Herabstufung | UBS | Neutral → Sell |
| 2022-09-15 | Hochstufung | Credit Suisse | Underperform → Neutral |
| 2022-09-08 | Herabstufung | Jefferies | Buy → Hold |
| 2022-08-05 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2022-07-21 | Fortgesetzt | Citigroup | Neutral |
| 2022-02-11 | Herabstufung | DZ Bank | Buy → Hold |
| 2021-11-05 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2021-06-24 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2021-03-23 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-04 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2021-01-20 | Herabstufung | Credit Suisse | Neutral → Underperform |
| 2021-01-15 | Eingeleitet | Deutsche Bank | Hold |
| 2020-11-02 | Hochstufung | Liberum | Hold → Buy |
| 2020-09-29 | Eingeleitet | Berenberg | Buy |
| 2020-02-12 | Herabstufung | Shore Capital | Hold → Sell |
| 2020-01-16 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2019-12-02 | Eingeleitet | SVB Leerink | Outperform |
| 2019-11-21 | Hochstufung | UBS | Neutral → Buy |
| 2019-10-11 | Hochstufung | Cantor Fitzgerald | Hold → Buy |
| 2019-09-03 | Fortgesetzt | Citigroup | Neutral |
| 2019-09-03 | Hochstufung | Societe Generale | Sell → Buy |
| 2019-08-13 | Fortgesetzt | JP Morgan | Neutral |
| 2019-06-17 | Fortgesetzt | Morgan Stanley | Underweight |
| 2019-03-08 | Herabstufung | Shore Capital | Buy → Hold |
| 2019-02-22 | Herabstufung | UBS | Buy → Neutral |
| 2019-01-14 | Herabstufung | Exane BNP Paribas | Outperform → Neutral |
| 2018-12-11 | Fortgesetzt | Jefferies | Buy |
| 2018-10-09 | Eingeleitet | Guggenheim | Neutral |
| 2018-08-30 | Herabstufung | Liberum | Buy → Hold |
| 2018-04-04 | Hochstufung | Exane BNP Paribas | Neutral → Outperform |
| 2018-03-22 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2018-02-09 | Hochstufung | Kepler | Reduce → Hold |
Alle ansehen
Gsk Plc Adr Aktie (GSK) Neueste Nachrichten
GSK plc Stock in December 2025: Buybacks, New CEO and Strong Q3 Results Drive a 40% Rally - ts2.tech
FDA Approves GSK's Drug, Targets Severe Asthma With Two Doses Per Year - Benzinga
GSK (NYSE:GSK) Major Shareholder Plc Gsk Purchases 1,470,000 Shares - Defense World
GSK plc Stock News Today (16.12.2025): Exdensur UK Approval Puts GSK Shares in Focus as FDA Decision Looms - ts2.tech
GSK (NYSE:GSK) Major Shareholder Purchases 1,470,000 Shares - MarketBeat
GSK's Nucala for COPD and Depemokimab for Asthma Get CHMP Nod in EU - Finviz
GSK plc Stock News & Forecasts (Dec. 15, 2025): FDA Catalyst for Depemokimab, EU Backs Nucala and Arexvy, Analysts Map the Path Ahead - ts2.tech
GSK plc Stock News Today (Dec. 13, 2025): EU and FDA Decisions Put Pipeline Momentum Back in Focus - ts2.tech
GSK Gets FDA Nod for Blujepa in Uncomplicated Urogenital Gonorrhea - Finviz
GSK (GSK) Scores Win in the Form of Lung Cancer Drug's Orphan Drug Designation - Finviz
GSK (GSK) Scores Win in the Form of Lung Cancer Drug’s Orphan Drug Designation - Insider Monkey
GSK (NYSE:GSK) Share Price Passes Above 200-Day Moving Average – Here’s Why - Defense World
GSK's Risvutatug Rezetecan Gets FDA's Orphan Drug Tag in Lung Cancer - Finviz
Is GSK PLC Gaining or Losing Market Support? - Sahm
13 Best ADR Stocks to Invest In - Insider Monkey
Best International Companies to Own: 2026 Edition - Morningstar
J.P. Morgan Maintains a Sell Rating on GSK plc (GSK) - Finviz
GSK Stock Near 52-Week Highs: Upgraded 2025 Guidance, Buybacks and Zantac Relief Fuel Re‑Rating - ts2.tech
GSK Stock Outlook December 2025: Q3 Beat, Buybacks and Big FDA Decisions Shape 2026 Forecasts - ts2.tech
AstraZeneca, GSK Among Executives Asked To Help Redesign UK Pricing Rules-Report - Sahm
Analysts Offer Predictions for GSK's Q2 Earnings (NYSE:GSK) - MarketBeat
Quantbot Technologies LP Has $5.33 Million Stock Holdings in GSK PLC Sponsored ADR $GSK - MarketBeat
GSK Stock Near 52‑Week High as FDA Decisions and CEO Transition Loom (LON:GSK, NYSE:GSK) - ts2.tech
Here's Why GSK (GSK) is a Strong Growth Stock - Yahoo Finance
GSK PLC Sponsored ADR $GSK Shares Acquired by Fisher Asset Management LLC - MarketBeat
GSK plc Stock Today: Q3 Beat, Blenrep Comeback and a New CEO – Full Investor Update for 2 December 2025 - ts2.tech
GSK Stock on 1 December 2025: Big 2025 Rally, Blenrep’s Comeback and a New CEO – What Investors Need to Know Now - ts2.tech
GSK PLC Sponsored ADR (NYSE:GSK) Receives Average Rating of “Hold” from Analysts - Defense World
GSK plc Stock Today, 28 November 2025: Buybacks, ‘Hold’ Ratings and Pipeline Momentum Keep Shares Near Highs - ts2.tech
Rep. Lisa C. McClain Sells Off Shares of GSK PLC Sponsored ADR (NYSE:GSK) - Defense World
GSK PLC Sponsored ADR (NYSE:GSK) Receives Average Rating of "Hold" from Analysts - MarketBeat
Looking To Buy GSK Plc ADR (GSK)? Read This First - fostersleader.com
GSK News Today (26 November 2025): Medicare Slashes Prices on Trelegy, Berenberg Lifts Target, and Buybacks Signal Confidence - ts2.tech
Rep. Lisa C. McClain Buys GSK PLC Sponsored ADR (NYSE:GSK) Stock - MarketBeat
Barclays PLC Share Price Today, 25 November 2025: BARC Jumps Above 409p as UK Budget Tax Fears Ease - ts2.tech
GSK (NYSE:GSK) Stock Unloaded Rep. Lisa C. McClain - MarketBeat
SG Americas Securities LLC Has $995,000 Stock Holdings in GSK PLC Sponsored ADR $GSK - MarketBeat
Zacks Research Issues Pessimistic Estimate for GSK Earnings - Defense World
Why GSK (GSK) is a Top Value Stock for the Long-Term - Yahoo Finance
Zacks Research Weighs in on GSK’s FY2025 Earnings (NYSE:GSK) - Defense World
JPMorgan Lowers GSK Price Target, Maintains Underweight Rating - Finviz
Alector Stock Plummets 63% in a Month: Here's What You Need to Know - Finviz
Eli Lilly Upgraded, Chewy Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
GSK PLC Share Price: What to Know Before the London Market Opens on 17 November 2025 - ts2.tech
GILD's Investigational Regimen for HIV Treatment Meets Primary Goal - Finviz
The Best Healthcare Stock to Hold in Uncertain Times - Finviz
Why GSK (GSK) is a Top Growth Stock for the Long-Term - Yahoo Finance
GSK (NYSE:GSK) Sets New 12-Month HighTime to Buy? - MarketBeat
AnaptysBio To Save $10 Million After Discontinuing Ulcerative Colitis Study - Sahm
Looking Into GSK PLC's Recent Short Interest - Sahm
3 Dividend Stocks for November 2025 - Morningstar
Finanzdaten der Gsk Plc Adr-Aktie (GSK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.35%
0.92%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):